A Phase 1 Study of PAmAb, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers | Zendy

G. Mani Subramanian | Zendy; P. Cronin | Zendy; Gerald E. Poley | Zendy; Arthur Weinstein | Zendy; Susan M. Stoughton | Zendy; John Zhong | Zendy; Y. Ou | Zendy; J. F. Zmuda | Zendy; Blaire L. Osborn | Zendy; William W. Freimuth | Zendy

Open Access

A Phase 1 Study of PAmAb, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers

Author(s) -

G. Mani Subramanian,

P. Cronin,

Gerald E. Poley,

Arthur Weinstein,

Susan M. Stoughton,

John Zhong,

Y. Ou,

J. F. Zmuda,

Blaire L. Osborn,

William W. Freimuth

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/430708

Subject(s) - medicine , bacillus anthracis , pharmacokinetics , adverse effect , placebo , pharmacology , bioavailability , toxin , anthrax vaccines , intramuscular injection , cohort , immunogenicity , antigen , immunology , pathology , microbiology and biotechnology , immunization , biology , dna vaccination , genetics , alternative medicine , bacteria

Inhibition of the binding of Bacillus anthracis protective antigen (PA) to its cellular receptor can abrogate the downstream toxin-mediated deleterious effects of the anthrax toxin. A fully human monoclonal antibody against B. anthracis PA, PAmAb, was previously shown to provide a survival advantage in rabbit and monkey models of inhalational anthrax.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research